| Followers | 144 |
| Posts | 28021 |
| Boards Moderated | 4 |
| Alias Born | 02/07/2004 |
Monday, July 20, 2009 10:02:49 AM
eps. Jeanette Mott Oxford and Rev. James Morris Endorse GenoMed's "Dialysis-Free in Five" Campaign
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
Lionel Nixon
Director, Field Operations
Legislative District 58
Missouri House of Representatives
lionelnixon@yahoo.com
Tel. 314-532-9902
The Honorable Jeanette Oxford
Representative, District 59
Missouri House of Representatives
jmo4rep@juno.com
Tel. 314-775-8940
ST. LOUIS—July 20, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today with pride that the Honorable Jeanette Mott Oxford and the Honorable James Morris have endorsed its campaign to make their districts at least 90% free of kidney disease by 2014.
GenoMed published in 2002 how to reverse early-stage kidney failure in patients with type 2 diabetes or high blood pressure. These two diseases cause over 90% of kidney failure that requires dialysis with the kidney machine.
Both Rep. Oxford's district in south St. Louis and Rep. Morris's district in north St. Louis each contain about 35,000 people. Their districts are among the oldest, most population-dense, and most ethnically and economically diverse districts in the state, including significant numbers of families living in poverty.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is the key to eliminating 90% of new cases of kidney failure. We'll be working with primary care providers and pharmacists in Districts 58 and 59 to identify and treat patients with diabetes and high blood pressure. We'll adjust their medications intensively over a period of 2 to 3 months. By the end of 2010, we hope to have covered every patient in both Districts."
Dr. Moskowitz added, "The drugs we use are generic and cheap. GenoMed's fees are low enough for everybody in these Districts to afford. Preventive molecular medicine is actually quite inexpensive, about 100 times cheaper than dialysis."
Dr. Moskowitz ended by saying, "I'm thrilled that Rep. Oxford and Rep. Morris are courageously leading their Districts to better public health. They live Missouri's motto, Salus populi suprema lex esto ["Let the health of the people be the supreme law"]. Their Districts are lucky to have them."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere. Please contact Dr. Moskowitz if you have one of these diseases.
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
Lionel Nixon
Director, Field Operations
Legislative District 58
Missouri House of Representatives
lionelnixon@yahoo.com
Tel. 314-532-9902
The Honorable Jeanette Oxford
Representative, District 59
Missouri House of Representatives
jmo4rep@juno.com
Tel. 314-775-8940
ST. LOUIS—July 20, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today with pride that the Honorable Jeanette Mott Oxford and the Honorable James Morris have endorsed its campaign to make their districts at least 90% free of kidney disease by 2014.
GenoMed published in 2002 how to reverse early-stage kidney failure in patients with type 2 diabetes or high blood pressure. These two diseases cause over 90% of kidney failure that requires dialysis with the kidney machine.
Both Rep. Oxford's district in south St. Louis and Rep. Morris's district in north St. Louis each contain about 35,000 people. Their districts are among the oldest, most population-dense, and most ethnically and economically diverse districts in the state, including significant numbers of families living in poverty.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is the key to eliminating 90% of new cases of kidney failure. We'll be working with primary care providers and pharmacists in Districts 58 and 59 to identify and treat patients with diabetes and high blood pressure. We'll adjust their medications intensively over a period of 2 to 3 months. By the end of 2010, we hope to have covered every patient in both Districts."
Dr. Moskowitz added, "The drugs we use are generic and cheap. GenoMed's fees are low enough for everybody in these Districts to afford. Preventive molecular medicine is actually quite inexpensive, about 100 times cheaper than dialysis."
Dr. Moskowitz ended by saying, "I'm thrilled that Rep. Oxford and Rep. Morris are courageously leading their Districts to better public health. They live Missouri's motto, Salus populi suprema lex esto ["Let the health of the people be the supreme law"]. Their Districts are lucky to have them."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere. Please contact Dr. Moskowitz if you have one of these diseases.
Recent GMED News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 09:03:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:20:59 PM
- Globus Medical Reports First Quarter 2026 Results • GlobeNewswire Inc. • 05/07/2026 08:15:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 02:33:57 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:06:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:04:33 PM
- Globus Medical Schedules First Quarter Earnings Release and Conference Call • GlobeNewswire Inc. • 04/16/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/14/2026 07:34:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 09:26:25 PM
- Globus Medical Announces Board Departure • GlobeNewswire Inc. • 03/23/2026 09:25:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 10:53:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/25/2026 08:41:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 10:08:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 09:23:38 PM
- Globus Medical Reports Fourth Quarter and Full Year 2025 Results • GlobeNewswire Inc. • 02/24/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:22:37 PM
- Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call • GlobeNewswire Inc. • 02/12/2026 09:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2026 05:12:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 10:10:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 10:05:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 10:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 10:01:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:59:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:56:45 PM
